Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00283283 · ClinicalTrials.gov registry record · Phase 2
Comparison of Full-dose Flu Vaccine to Half-dose Flu Vaccine
A Phase 2 study, sponsored by U.S. Army Medical Research and Development Command.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,316
- Enrollment target
NCT00283283: Completed Phase 2 study, sponsored by U.S. Army Medical Research and Development Command.
NCT00283283 is a Phase 2 study that has completed, run by U.S. Army Medical Research and Development Command. The registered enrollment target is 1,316 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (889% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00283283, a Phase 2 study, has completed, sponsored by U.S. Army Medical Research and Development Command.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,316 participants
- Enrollment target
Study Summary
This study compared full-dose Flu vaccine to half-dose Flu-vaccine during the 2004-2005 flu season.
Primary Outcome
Immune response as measured by viral strain specific hemaggluttination inhibition (HAI) antibody levels for subjects ages 18-49
Interventions
- BIOLOGICAL Fluzone® (Aventis Pasteur inactivated influenza vaccine)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,316 participants |
| Start Date | 2004-11 |
| Est. Completion | 2006-05 |
| Phase | Phase 2 |
What the finished NCT00283283 record still lists
NCT00283283 is an interventional study that assigns participants to a tested intervention. Its 1,316 participants enrollment target places it among the larger protocols in the corpus, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (889% higher).
The record links to 0 conditions, and to 1 intervention - of which Fluzone® (Aventis Pasteur inactivated influenza vaccine) is the first listed.
NCT00283283 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00283283 about?
NCT00283283 is a clinical study titled "Comparison of Full-dose Flu Vaccine to Half-dose Flu Vaccine". This study compared full-dose Flu vaccine to half-dose Flu-vaccine during the 2004-2005 flu season.
What is the current status of trial NCT00283283?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,316 participants. The study started on 2004-11. Estimated completion is 2006-05.
What interventions are being tested in trial NCT00283283?
The interventions under investigation include: Fluzone® (Aventis Pasteur inactivated influenza vaccine) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00283283?
This trial is sponsored by U.S. Army Medical Research and Development Command, which has 77 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00283283's enrollment target sits among peer trials
1,316 13th of 2000 higher than 1,988 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05762302 · 1,316 participants · NA
The Impact of MeMed BV® on Management of Patients With Suspected Lower Respiratory Tract Infections (LRTI) in the Emergency Department (ED) and Urgent Care Center (UCC) ("JUPITER" TRIAL)
- NCT05176483 · 1,314 participants · Phase 1
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
- NCT06136650 · 1,314 participants · Phase 3
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
- NCT07144800 · 1,319 participants · NA
Family COMIDA (Consumo de Opciones Más Ideales De Alimentos) (Eating More Ideal Food Options)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia